Veeva reported better-than-expected sales and earnings in August. The stock's valuation ratios tumbled, while it lagged major indexes over the past year. Veeva's valuation suddenly looks cheap when ...

Veeva Systems (VEEV) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Over ...

If you are wondering whether Veeva Systems at around US$156 still makes sense for your portfolio, the starting point is understanding what that price actually reflects about the business. The share ...

Veeva saw its revenue and non-GAAP operating income grow 13% and 29% YoY in its Q3 FY25 earnings, beating estimates with ongoing momentum in its Development Cloud. The Development Cloud segment, now ...

Veeva Systems (VEEV) closed at $163.78 in the latest trading session, marking a -2.39% move from the prior day. This move lagged the S&P 500's daily gain of 1.05%. On the other hand, the Dow ...

As cloud-software firm Veeva Systems races to keep up with the growth of its clients in the life sciences sector, the California-based company is turning to the Boston labor market for some help, with ...

Veeva Systems Inc (NYSE:VEEV) is among the best medical AI stocks to buy now. Wall Street is taking note of Veeva’s AI ...

Despite a reduction in guidance for FY 2023, Veeva Systems still has strong growth prospects in the healthcare sector. The potential for the Fed to stop raising interest rates could provide more ...

Veeva Systems Inc. (NYSE:VEEV) is one of the most oversold healthcare stocks to invest in. Veeva Systems Inc. (NYSE:VEEV) was ...

Veeva is the leading provider of cloud-based software solutions tailored to the life sciences industry, providing an ecosystem of products to address the operating challenges and regulatory ...

I wore the world's first HDR10 smart glasses TCL's new E Ink tablet beats the Remarkable and Kindle Anker's new charger is one of the most unique I've ever seen Best laptop cooling pads Best flip ...

Despite a strong long-term opportunity, a slowing economy could hurt the company's near-term prospects. Veeva's revenue growth should improve when the funding environment for smaller biotech companies ...